Clinical Trial Update: Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This update covers a phase 1/2 clinical trial evaluating a vaccine therapy with or without interleukin-2 for stage III or stage IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Vaccine therapy (undisclosed)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Melanoma (Skin) | Phase 1, Phase 2 | Status: UNKNOWN